文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

使用Vela自动化二代测序平台进行HIV-1基因型耐药检测

HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

研究评估Vela自动化二代测序(NGS)系统联合Sentosa SQ HIV基因分型试剂盒对HIV-1进行基因分型的诊断性能,并与直接测序、454 GS-FLX和MiSeq系统比较。Vela在500拷贝/mL可检测B亚型和CRF02-AG样本的主要耐药突变,在100 000拷贝/mL时检测少数变异灵敏度为5%,与直接测序一致率97%,但检测少数变异灵敏度低于其他NGS平台。

要点

  • Vela系统在500拷贝/mL检测B亚型和CRF02-AG主要耐药突变,100 000拷贝/mL时少数变异灵敏度5%。
  • Vela与直接测序在46份临床样本中鉴定耐药突变一致率97%。
  • Vela检测少数变异灵敏度低于454和MiSeq,>20%突变检出率高。

核心结论

  • Vela NGS系统提供自动化核酸提取、PCR试剂分配、文库制备和生物信息学分析,与直接测序相比分析性能很好,但检测少数变异灵敏度低于其他两个NGS平台。

研究设计与样本

  • 研究评估Vela NGS系统联合Sentosa SQ HIV基因分型试剂盒对HIV-1进行基因分型,血浆RNA提取后用Sentosa SX仪器制备模板,在Sentosa SQ301测序仪(PGM IonTorrent)上测序HIV-1聚合酶。
  • Vela NGS系统与直接测序、454 GS-FLX(Roche)和MiSeq(Illumina)系统在临床样本上进行基因型耐药检测比较。

主要发现

  • Vela NGS系统在500拷贝/mL检测B亚型和CRF02-AG样本的主要耐药突变,在100 000拷贝/mL检测少数变异灵敏度为5%。
  • Vela NGS系统与直接测序在46份临床样本中鉴定耐药突变一致率97%。
  • Vela检出454鉴定的1%-5%突变中1/20、5%-20%突变中5/12、>20%突变中60/61。
  • Vela检出MiSeq鉴定的1%-5%突变中3/14、5%-20%突变中0/2、>20%突变中47/47。
  • Vela与454的耐药突变定量一致(偏倚2.31%),Vela与MiSeq的定量一致(偏倚1.06%)。

局限性

  • Vela检测少数变异的灵敏度低于其他两个NGS平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the diagnostic performance of the Vela next-generation sequencing (NGS) system in conjunction with the Sentosa SQ HIV Genotyping Assay for genotyping HIV-1. METHODS: Plasma RNA was extracted and templates prepared with the Sentosa SX instrument before sequencing the HIV-1 polymerase on the Sentosa SQ301 Sequencer (PGM IonTorrent). The Vela NGS System was compared with direct sequencing and the 454 GS-FLX (Roche) and MiSeq (Illumina) systems for genotypic resistance testing on clinical samples. RESULTS: The Vela NGS system detected majority resistance mutations in subtype B and CRF02-AG samples at 500 copies/mL and minority variants with a sensitivity of 5% at 100 000 copies/mL. The Vela NGS system and direct sequencing identified resistance mutations with 97% concordance in 46 clinical samples. Vela identified 1/20 of the 1%-5% mutations identified by 454, 5/12 of the 5%-20% mutations and 60/61 of the >20% mutations. Vela identified 3/14 of the 1%-5% mutations identified by MiSeq, 0/2 of the 5%-20% mutations and 47/47 of the >20% mutations. The resistance mutation quantifications by Vela and 454 were concordant (bias: 2.31%), as were those by Vela and MiSeq (bias: 1.06%). CONCLUSIONS: The Vela NGS system provides automated nucleic acid extraction, PCR reagent distribution, library preparation and bioinformatics analysis. The analytical performance was very good when compared with direct sequencing, but was less sensitive than two other NGS platforms for detecting minority variants.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Raymond S, Nicot F, Carcenac R, et al. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform. J Antimicrob Chemother. 2018. PMID: 29444253. doi:10.1093/jac/dky003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。